{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-25-000089","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.253808+00:00","generated_at":"2026-05-16T21:47:19.288433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alto Neuroscience Q3 net loss $14.2M; cash $184.2M after $50M PIPE; ALTO-207 on track for Phase 3 by early 2027","bullets":["Net loss $14.2M vs $16.8M in Q3 2024; R&D expense $10.5M, G&A $4.4M.","Cash $184.2M as of Oct 31 (incl. $49.9M net PIPE proceeds), projected to fund operations into 2028.","ALTO-207 Phase 2b TRD trial start 1H 2026; Phase 3 by early 2027 after successful FDA meeting.","Topline data expected: ALTO-101 CIAS (1Q 2026), ALTO-300 MDD (mid-2026), ALTO-100 BPD (2H 2026).","ALTO-101 granted FDA Fast Track Designation for CIAS; blinded PK analyses showed 100% positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-25-000089","json":"https://secwatch.observer/filing/0001999480-25-000089.json","markdown":"https://secwatch.observer/filing/0001999480-25-000089.md","text":"https://secwatch.observer/filing/0001999480-25-000089.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/0001999480-25-000089-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948025000089/alto-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:47:19.288433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}